Balyasny Asset Management’s Altimmune ALT Stock Holding History

Balyasny Asset Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,109	Closed	-$217K	–	2848
2025 Q4	$217K	Buy	+60,109	New	+$262K	﹤0.01%	2854
2025 Q2	–	Sell	-54,953	Closed	-$297K	–	2767
2025 Q1	$275K	Sell	54,953 -141,374	-72%	-$896K	﹤0.01%	2481
2024 Q4	$1.42M	Buy	196,327 +16,387	+9%	+$125K	﹤0.01%	1803
2024 Q3	$1.1M	Buy	+179,940	New	+$1.22M	﹤0.01%	1930
2023 Q4	–	Sell	-947,578	Closed	-$2.46M	–	2460
2023 Q3	$2.46M	Buy	947,578 +248,051	+35%	+$712K	0.01%	1324
2023 Q2	$2.47M	Buy	699,527 +208,839	+43%	+$938K	0.01%	1312
2023 Q1	$2.07M	Buy	490,688 +310,940	+173%	+$3.69M	0.01%	1447
2022 Q4	$2.96M	Sell	179,748 -857,914	-83%	-$9.64M	0.01%	1250
2022 Q3	$13.3M	Buy	1,037,662 +831,193	+403%	+$12.3M	0.04%	574
2022 Q2	$2.42M	Buy	+206,469	New	+$1.27M	0.01%	1315

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Balyasny Asset Management's ALT Position: Q1 2026 in Review

Balyasny Asset Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 60,109 shares — an estimated $217K sold.

Balyasny Asset Management first reported a position in ALT in Q2 2022 and held it in 10 quarters. The position peaked at $13.3M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Balyasny Asset Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 60,109 Altimmune shares in Q1 2026, an estimated $217K.
Balyasny Asset Management first reported a position in Altimmune in Q2 2022 and held it in 10 quarters.
Balyasny Asset Management's Altimmune position peaked at $13.3M in Q3 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.